About this trial
Coronary artery disease is a leading cause of mortality and morbidity globally. The left coronary artery system is critically important due to its supply of a large area of myocardium. Ostia lesions of left anterior descending artery \[LAD\] and circumflex artery \[CX\]) present technical challenges during percutaneous coronary intervention (PCI) and are considered high-risk lesions due to their anatomical location, relationship with the left main coronary artery bifurcation. Two main approaches exist for treating these lesions: accurate ostial stenting and crossover stenting extending from the left main coronary artery to the relevant branch. Accurate ostial stenting aims to avoid unnecessary stenting of the left main coronary artery, while crossover stenting is more advantageous in terms of ensuring complete coverage of the ostial region. However, the crossover approach may have disadvantages such as larger stent implantation and potential side branch involvement. The current literature does not clearly define the clinical superiority of these two strategies. While various studies have shown no significant difference in mortality, myocardial infarction, and target lesion revascularization, the results are heterogeneous, and a definitive consensus has not been reached. The majority of current data are based on retrospective or observational studies. Therefore, well-designed prospective studies comparing crossover stenting and accurate ostial stenting strategies in the ostial left-sided coronary artery (LAD and CX) lesions are needed. This planned study aims to contribute to this gap in the literature by comparing the clinical outcomes of the two approaches.
Eligibility criteria
Qualifiers
Ostial left anterior descending artery or left circumflex artery disease
Coronary intervention with second or third generation drug-eluting stent
Disqualifiers
Severe left main disease (≥30%, intravascular ultrasound plaque burden >50%)
History of coronary bypass grafting
Cardiogenic shock
Left main diameter greater than stent expansion capacity (for crossover group)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Istanbul Mehmet Akif Ersoy Educational and Training Hospital
Lead sponsor
Yalova training and research hospital
Collaborator
Mersin City Hospital
Collaborator
Van Training and Research Hospital
Collaborator
Başakşehir Çam & Sakura City Hospital
Collaborator
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Collaborator
Trakya University
Collaborator
Sisli Hamidiye Etfal Training and Research Hospital
Collaborator
Istanbul Training and Research Hospital
Collaborator
Medipol University
Collaborator
Samsun Education and Research Hospital
Collaborator
Kocaeli University
Collaborator
Abant Izzet Baysal University
Collaborator
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
Collaborator
Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
Collaborator
Bagcilar Training and Research Hospital
Collaborator
Ankara City Hospital Bilkent
Collaborator
Dicle University
Collaborator
Bursa Yuksek Ihtisas Training and Research Hospital
Collaborator
Haseki Training and Research Hospital
Collaborator
Ahi Evran University Education and Research Hospital
Collaborator
Ankara Etlik City Hospital
Collaborator
Izmir Bakircay University
Collaborator
Istanbul Medipol University Hospital
Collaborator
Kutahya City Hospital
Collaborator
Adiyaman University Research Hospital
Collaborator
Adana City Training and Research Hospital
Collaborator
Kosuyolu Heart Hospital
Collaborator
Ege University
Collaborator
Bursa City Hospital
Collaborator
Bilecik Seyh Edebali Universitesi
Collaborator
Siirt Training and Research Hospital
Collaborator
Hitit University
Collaborator